These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 16835191

  • 41. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
    Karst KR.
    Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732
    [No Abstract] [Full Text] [Related]

  • 42. Policy developments in regulatory approval.
    Temple R.
    Stat Med; 2002 Oct 15; 21(19):2939-48. PubMed ID: 12325110
    [Abstract] [Full Text] [Related]

  • 43. Policy currents. FDA addresses backlog of generic medication applications.
    Consult Pharm; 2006 May 15; 21(5):419-21. PubMed ID: 16929569
    [No Abstract] [Full Text] [Related]

  • 44. Regulatory considerations for determining postmarketing study commitments.
    Meyer RJ.
    Clin Pharmacol Ther; 2007 Aug 15; 82(2):228-30. PubMed ID: 17538552
    [Abstract] [Full Text] [Related]

  • 45. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
    Cross J, Lee H, Westelinck A, Nelson J, Grudzinskas C, Peck C.
    Pharmacoepidemiol Drug Saf; 2002 Sep 15; 11(6):439-46. PubMed ID: 12426927
    [Abstract] [Full Text] [Related]

  • 46. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT.
    Food Drug Law J; 2007 Sep 15; 62(3):559-72. PubMed ID: 17915397
    [No Abstract] [Full Text] [Related]

  • 47. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK.
    Food Drug Law J; 2006 Sep 15; 61(3):577-83. PubMed ID: 16989041
    [No Abstract] [Full Text] [Related]

  • 48. Maine law requires drug companies to provide clinical trial data.
    Appell D.
    J Natl Cancer Inst; 2005 Sep 07; 97(17):1246. PubMed ID: 16145043
    [No Abstract] [Full Text] [Related]

  • 49. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL.
    Arch Intern Med; 2006 Oct 09; 166(18):1938-42. PubMed ID: 17030825
    [Abstract] [Full Text] [Related]

  • 50. Marketing off-label uses to physicians: FDA's draft (mis)guidance.
    Gass A, Wilson J.
    Am J Bioeth; 2008 Mar 09; 8(3):1-3. PubMed ID: 18570084
    [No Abstract] [Full Text] [Related]

  • 51. Administration of a large nesiritide bolus dose in a pediatric patient: case report and review of nesiritide use in pediatrics.
    Moffett BS, Jefferies JL, Price JF, Clunie S, Denfield S, Dreyer WJ, Towbin JA.
    Pharmacotherapy; 2006 Feb 09; 26(2):277-80. PubMed ID: 16466333
    [Abstract] [Full Text] [Related]

  • 52. TransMolecular receives FDA approval for 131-I-TM-601 IND application.
    Expert Rev Anticancer Ther; 2002 Apr 09; 2(2):139. PubMed ID: 12113233
    [No Abstract] [Full Text] [Related]

  • 53. Nesiritide for acute decompensated heart failure: does the benefit justify the risk?
    Sackner-Bernstein J, Aaronson KD.
    Curr Cardiol Rep; 2007 May 09; 9(3):187-93. PubMed ID: 17470331
    [Abstract] [Full Text] [Related]

  • 54. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI.
    Drug News Perspect; 2009 May 09; 22(1):30-8. PubMed ID: 19209297
    [Abstract] [Full Text] [Related]

  • 55. FDA set to tighten guidelines on industry dissemination of information on unapproved uses of medical products.
    Lang L.
    Gastroenterology; 2008 Apr 09; 134(4):905. PubMed ID: 18395067
    [No Abstract] [Full Text] [Related]

  • 56. Nesiritide utilization evaluation in a university teaching hospital.
    Cheng JW, Merl MY, Nguyen HM, Caliendo GC, Meyers J.
    J Clin Pharm Ther; 2005 Oct 09; 30(5):447-53. PubMed ID: 16164491
    [Abstract] [Full Text] [Related]

  • 57. [Drug policy 1996].
    Bogaert M.
    Verh K Acad Geneeskd Belg; 1997 Oct 09; 59(4):227-36. PubMed ID: 9490919
    [Abstract] [Full Text] [Related]

  • 58. Pharmaceutical industry perspective on risk evaluation and mitigation strategies: manufacturer take heed.
    Nicholson S, Peterson J, Yektashenas B.
    Expert Opin Drug Saf; 2012 Mar 09; 11(2):299-314. PubMed ID: 22233294
    [Abstract] [Full Text] [Related]

  • 59. The FDA and "privatization"--the drug approval process.
    Rutherford EM.
    Food Drug Law J; 1995 Mar 09; 50 Spec():203-25. PubMed ID: 10343044
    [No Abstract] [Full Text] [Related]

  • 60. Sporicidin responds to the recall of its products.
    Healthc Hazard Mater Manage; 1992 Aug 09; 5(11):8-11. PubMed ID: 10121070
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.